What is the difference between tenofovir and entecavir?
Tenofovir and entecavir are regarded as first-line anti-hepatitis B virus because of their strong antiviral activity, low resistance and good safety, and Pegasys in interferon.
According to the classic clinical trial, one year treatment of tenofovir and entecavir, the anti-virus effects were compared as follows:
HBV DNA in patients with HBeAg (+) reduced tenofovir 1.58x10 6th power; entecavir 7.9x10 6x copies / mL
"Sanyang" to "Sanyang" are 21%
HBV DNA in ten patients with HBeAg (-) decreased tenofovir 3.98 x 10 in the fifth power; entecavir 1.00 x 10 in 5 copies / mL
Tenofovir is also effective in patients with lamivudine-resistant and non-resistant patients.
Use of entecavir for adefovir-resistant patients is as effective as non-drug resistant patients.
Because the above results are obtained from two separate clinical trials, not the same conditions in the same test obtained, only for reference.